Search

Displaying results 6881 - 6890 of 8468 in total
  1. Drug

    Remlifanserin

    go.drugbank.com/drugs/DB21707
    Experimental

    Remlifanserin has a monoisotopic molecular weight of 429.22 Da.

  2. Drug

    Envudeucitinib

    go.drugbank.com/drugs/DB21716
    Investigational

    Envudeucitinib has a monoisotopic molecular weight of 426.23 Da.

  3. Drug

    Zemprocitinib

    go.drugbank.com/drugs/DB21719
    Experimental

    Zemprocitinib has a monoisotopic molecular weight of 345.13 Da.

  4. Drug

    Bencyclane

    go.drugbank.com/drugs/DB13488
    Experimental

    It has various other potentially useful pharmacological effects. Its mechanism may involve block of calcium channels.

  5. Drug

    Bimagrumab

    go.drugbank.com/drugs/DB12584
    Investigational

    Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis

  6. Drug

    Acetylcysteine zidrimer

    go.drugbank.com/drugs/DB16496
    Investigational

  7. Drug

    Resveratrol

    go.drugbank.com/drugs/DB02709
    Investigational

    It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. … It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr.

  8. Drug

    Palmidrol

    go.drugbank.com/drugs/DB14043
    InvestigationalNutraceutical

    Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets). … A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection.

  9. Drug

    Gadoxetic acid

    go.drugbank.com/drugs/DB08884
    ApprovedInvestigational

    [A263156] Gadoxetate is a unique gadolinium-based contrasting agent (GBCA) with both dynamic phase and hepatobiliary phase and thus has different pharmacokinetic and pharmacodynamic properties compared

  10. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to